DNB Bank ASA (DNB)
Verdict history · DNB
Period return = price change from verdict date to next verdict date (or present for Active). Prices are from published frontmatter — a stated fact, not a live feed. Full track record →
Hold DNB with conviction. Here’s why the panel thinks it’s a WAIT, and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
Oslo Børs (OSL) · Financials / Banking · 2026-07-14 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 295.3 (July 14, 2026)
DNB reported Q2 2026 earnings today — net interest income fell NOK 167 million quarter-on-quarter on margin compression (NIM down to 1.70% from 1.74%), but fee income rose 4.6% year-over-year and ROE held at a healthy 14.6% on fortress capital (CET1 17.4%, nearly double regulatory minimums). The panel's verdict is: good business, fair price, wait for confirmation. Two investors (The Moat Compounder, The Asymmetry Hunter) say buy now; four say wait for Q3 earnings (Oct 21) or a pullback to NOK 260–280; one (The Valuation Engineer) leans cautious, valuing fair value at NOK 263 (−12% downside). All agree the balance sheet is pristine, management is disciplined, and insider buying validates confidence — but "fair price" for a 14.6% ROE bank is not the same as a margin-of-safety price. The shortage of conviction reflects a simple split: are you paying up now for cyclical margin recovery five weeks away, or do you wait for proof and a better entry? Five of six frameworks answer "wait."
Key levels
Key levels · DNB
NOK · as of 2026-07-14S1 · 282.7 · −4.3% from current
200-day MA / uptrend support
S2 · 260 · −12.0% from current
Value-investor conviction zone
S3 · 270 · −8.6% from current
Through-cycle fair value
Analyst consensus target 303.7 NOK · range 200–350
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Resistance: The 52-week high at NOK 313.6 is the first overhead shelf; the stock barely moved on today's NII miss, showing uptrend resilience. A break and hold above 314 would signal bullish technical confirmation and likely attract momentum into the Q3 earnings catalyst (Oct 21). Round-number projection levels sit near NOK 320–330, though a parabolic-top formation has little historical overhead structure.
Current price: NOK 295.3 (July 14, 2026, on the day of earnings) sits comfortably inside the uptrend (~5.6% above the 200-day MA), pricing in fair value for a quality Nordic bank with a 6% yield. No margin of safety at this level per The Margin of Safety Guardian's framework (13% vs the 20–25% required); modest −12% downside per The Valuation Engineer's DCF.
Support: The 200-day MA at NOK 282.7 is the first-line uptrend support; loss of this level would signal trend break and likely open a deeper pullback. Secondary support clusters at NOK 260–280, where value-oriented investors seek conviction entry (20–25% margin of safety restores). Through-cycle fair value (normalized margins, normalized earnings) sits deeper still, NOK 200–250, representing the "terminal value" if NIM compression proves structural rather than cyclical.
Analyst consensus: Consensus target spans NOK 200 (bubble call) to NOK 350 (bull call), averaging NOK 303.7 — notably below the current price, implying consensus is chasing the move rather than leading. The Valuation Engineer models NOK 263 base case (−12% downside). The wide target spread reflects genuine disagreement about whether the repricing catalyst (Q3 Oct 21) validates management's margin-recovery thesis.
Key catalyst timing: Q3 earnings on October 21 will either validate the repricing story (NII re-accelerates QoQ) and likely test R1/R2 levels, or confirm margin-pressure continues and open the S2 pullback zone.
What legendary investors think
We ran DNB past a panel of six legendary investors' frameworks.
The panel · 7 investors
5 neutral · 2 bullishMCThe Moat CompounderValueBullish70% conviction
"The market confuses cyclical margin squeeze with permanent business damage. The moat — #1 in Norway — is intact. Management is doing exactly what I want: rising dividends, buybacks from real surplus, not chasing growth for its own sake. Fair price for quality; at NOK 295 you're paying a fair price for a good business, not a bargain price. But the 6% yield makes it reasonable for patient income holders."
AHThe Asymmetry HunterDhandhoBullish72% conviction
"Heads I win: NII recovers in Q3, buyback shrinks the float, I collect 6% while re-rating happens. Tails I don't lose much: fortress balance sheet at 1.48x book, 99.4% clean loans, CET1 cushion double regulatory minimums. Chair, board members, and management all bought 161k+ shares at NOK 286–291 in May–June — that's coordinated confidence from people who know the loan book. Dhandho score 7/10: good odds, real edge, capital preserved either way."
VAThe Value ArchitectValueNeutral60% conviction
"Good business, fair price, not a bargain. I want three quarters of ROE above 15% before calling this 'wonderful' — it's currently 14.6%, below my threshold. Or a pullback to NOK 220–240 giving me the 25–40% discount I require. At roughly 10x earnings on a 14.6% ROE, you're paying fair value, maybe a touch rich. The 6% yield softens the blow of waiting, but this isn't the fat pitch I'd swing hard at."
MOThe Margin of Safety GuardianMargin of SafetyNeutral58% conviction
"Checklist score: 5/8 passes (middling). Fair value by intrinsic-value formula NOK 339 vs current NOK 295 = 13% margin of safety (thin; I want 20–25%). Earnings are cyclical — normalized mid-cycle P/E likely 11–12x, not the flattering 10x on peak-adjacent earnings. Fortress capital is a plus; dividend record is solid (COVID suspension in 2020 was industry-wide). Bullish trigger: decline to NOK 260–270 OR proof that compression stabilizes."
GOThe GARP OperatorGARPNeutral58% conviction
"This isn't a growth stock — it's a Slow Grower / Sluggard. No ten-bagger here. Earnings declining ~6–9% YoY; PEG is inapplicable with negative growth. The right question: is 10.7x P/E + 6% yield adequate compensation for the decline? Every quarter I'd verify that fee income growth (+4.6% YoY) offsets NIM erosion. If the offset breaks, dividend coverage tightens and I reassess. Mature market, dominant incumbent — this is income-and-patience, not a compounder."
VEThe Valuation EngineerDCFNeutral55% conviction
"My excess-return DCF fair value: NOK 263 (−12% downside at current). Market already priced in the bull case (Q3 recovery + Nov CMD uplift). Valuation hinges on one assumption: how much of current 14.6% ROE is cyclical vs structural? Everything else moves by single digits; this moves by 30%+. Sensitivity: bear NOK 215 (ROE → 8.5%), base NOK 263 (ROE fade 14%→9%), bull NOK 319 (NII stabilizes, targets raised). I'd rather wait for Q3 confirmation or a pullback before conviction sizing."
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The numbers right now are genuinely strong: ROE 14.6%, NIM held despite Q2 pressure, fee income +4.6% YoY, CET1 17.4%, 99.4% Stage 1/2 loans — a fortress balance sheet with operational strength.
- Margin compression is cyclical, not structural: rate-driven (July 12 repricing, Aug 2026 potential hike), not credit-driven; banks have navigated this many times before.
- Management is disciplined: rising dividend, buybacks from real surplus capital (not financial engineering), insider buying validates confidence.
- Q3 earnings (Oct 21) and November Capital Markets Day are the catalysts: these will either validate the margin-recovery thesis or confirm the bears' worry that structural headwinds persist.
- The 6% yield is doing real work: dividend + buyback provide a return floor while you wait for clarity.
The real debate
- Fair price vs. margin-of-safety price: Bulls (The Moat Compounder, The Asymmetry Hunter) say NOK 295 is fair-to-cheap; cautious investors (The Margin of Safety Guardian and value-oriented investors) want NOK 260–280 (20–25% discount) before real conviction. The gap is whether you trust the repricing catalyst enough to pay full value now.
- Cyclical trough or structural shift: Everyone agrees margins compressed; they disagree whether Q3 proves the trough is near or shows further deterioration. Management says July 12 repricing will support Q3 NII — that's the next five weeks' story.
- Earnings durability: Valuation Engineer says normalized through-cycle margin is lower than today's 1.70%; mid-cycle is ~1.1–1.2%; GARP Operator says fee income offset is temporary. Bull view is both pressure and offset normalize at higher absolute levels.
- Entry timing: Two say buy now (insider confidence, fortress balance sheet); four say wait (better entry or confirmation needed); one leans cautious on valuation. The consensus is not "pass" — it's "wait for data."
The question it comes down to: Do you trust the Q3 repricing catalyst and pay fair value now, or do you wait for confirmation and potentially get a better entry in the NOK 260–280 zone? Five of six frameworks say "wait."
The numbers
| Metric | Value | Assessment |
|---|---|---|
| Price / Market cap | NOK 295.3 / |
Current day of earnings; recent range NOK 282–315 |
| P/E (TTM) | ~10.7x | Fair for quality; not cheap vs Nordic peers (Nordea ~11.5x, SEB ~13x) |
| P/B | 1.48x | In-line with Nordic banks; no bargain relative to ROE ranking |
| ROE (Q2) | 14.6% | Down from 16.6% (Q4 2025); below 15% "excellent" threshold |
| Dividend Yield | 6.0% | Solid; payout ratio 58–63% (sustainable, covers earnings) |
| CET1 Ratio | 17.4% | Fortress capital; ~100bps above regulatory minimums |
| Stage 1/2 Loans | 99.4% | Pristine asset quality; zero hidden credit stress |
| NIM (Q2) | 1.70% | Down from 1.74% (Q1); spreads compressing (1.73% Q3 2025 → 1.52% Q1 2026) |
| Fee Income Growth (YoY) | +4.6% | Genuine offset to NII pressure; diversification working |
| Insider Buying (H1 2026) | 161k+ shares @ NOK 286–291 | Chair, board, management all buying — bullish signal |
| Analyst Consensus Target | NOK 303.7 | ~1.8% upside; "Hold" consensus; minimal new conviction |
Figures from DNB Q2 2026 (quarter ended June 30, reported July 14) / current pricing mid-day July 14, 2026; sourced from DNB IR, Investing.com, stockanalysis.com, Stockopedia. Through-cycle fair values per investor models: The Value Architect ~NOK 220–240, The Margin of Safety Guardian NOK 260–270, The Valuation Engineer NOK 263, The Macro Navigator ~NOK 200–250. Current price reflects all known earnings data.
The bottom line
DNB is the panel's clearest "quality at fair price" call — and the caution comes despite genuinely impressive numbers. The fortress balance sheet (CET1 17.4%, 99.4% Stage 1/2), the insider buying, the 6% yield, and the management-guided repricing catalyst (July 12 → Q3 earnings Oct 21) are all real and bullish. But five of six frameworks — value, growth, quantitative, macro, and fundamental — reach the same conclusion for the same reason: this is a cyclical margin compression in a commoditized banking market, fair price is not the same as a margin-of-safety price, and the next five weeks will either validate the recovery thesis or confirm structural headwinds persist. Normalized through-cycle fair value sits well below the current price (NOK 200–270, depending on model), consensus targets sit around NOK 303 (essentially flat), and the margin of safety at NOK 295 is thin per The Margin of Safety Guardian's framework (13%), modestly negative per The Valuation Engineer (−12% to fair value). What would change the call is a Q3 earnings print showing NII re-accelerating quarter-on-quarter and a November Capital Markets Day confidence reaffirmation — at which point the four cautious investors upgrade to BUY. What keeps this a WAIT is that absent that confirmation, buyers are paying a fair price in a cyclical trough year for a business whose earnings history shows mean-revert hard when the cycle turns. The magnitude of management's insider buying and the outsized 6% yield are why conviction is Medium, not high; the direction — wait for confirmation or pullback — is not in much doubt.
This is analysis, not investment advice. Consult a qualified financial advisor before making any investment decisions.
Catalyst calendar: July 12 repricing (passed) · August 2026 potential Norges Bank hike · October 21 Q3 earnings (critical test) · November 10 Capital Markets Day (guidance reset)
Next review trigger: Q3 earnings confirmation or technical break of NOK 313.6 resistance
contact@verdixhq.com · Published 2026-07-14 · Prices as of 2026-07-14 · Time horizon: 3–12 months · Analysis reflects multi-perspective investor debate. No material conflicts; verdicts are educational synthesis, not personalized recommendations. · DNB verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated